Cargando…
Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia
BACKGROUND: 5-Azacitidine administered as a 7-day dosing regimen (7–0-0) is approved in high risk IPSS myelodysplastic syndrome (MDS) patients. Alternative regimens such as a 5-day (5–0-0) or 7-day with a weekend break (5–2-2) are commonly used. No randomized controlled trial has been done directly...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5793426/ https://www.ncbi.nlm.nih.gov/pubmed/29435331 http://dx.doi.org/10.1186/s12878-017-0094-8 |